Breast cancer stage and molecular subtype distribution: real-world insights from a regional oncological center in Hungary.

Autor: Tittmann J; Center for Health Technology Assessment, Semmelweis University, Üllői Str 25, Budapest, 1091, Hungary. aghne.judit@phd.semmelweis.hu.; Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary. aghne.judit@phd.semmelweis.hu., Ágh T; Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary.; Syreon Research Institute, Budapest, Hungary., Erdősi D; Center for Health Technology Assessment, Semmelweis University, Üllői Str 25, Budapest, 1091, Hungary.; Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary., Csanády B; Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary., Kövér E; Department of Oncotherapy, Medical School and Clinical Center, University of Pécs, Pécs, Hungary., Zemplényi A; Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary.; Syreon Research Institute, Budapest, Hungary., Kovács S; Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary.; Syreon Research Institute, Budapest, Hungary., Vokó Z; Center for Health Technology Assessment, Semmelweis University, Üllői Str 25, Budapest, 1091, Hungary.; Syreon Research Institute, Budapest, Hungary.
Jazyk: angličtina
Zdroj: Discover oncology [Discov Oncol] 2024 Jun 22; Vol. 15 (1), pp. 240. Date of Electronic Publication: 2024 Jun 22.
DOI: 10.1007/s12672-024-01096-9
Abstrakt: Objective: Examining the distribution of breast cancer (BC) stage and molecular subtype among women aged below (< 45 years), within (45-65 years), and above (> 65 years) the recommended screening age range helps to understand the screening program's characteristics and contributes to enhancing the effectiveness of BC screening programs.
Methods: In this retrospective study, female patients with newly diagnosed BC from 2010 to 2020 were identified. The distribution of cases in terms of TNM stages, severity classes, and subtypes was analysed according to age groups.
Results: A total of 3282 women diagnosed with BC were included in the analysis. Among these cases 51.4% were detected outside the screening age group, and these were characterized by a higher TNM stage compared to those diagnosed within the screening age band. We observed significantly higher relative frequency of advanced BC in the older age group compared to both the screening age population and women younger than 45 years (14.9% vs. 8.7% and 7.7%, P < 0.001). HR-/HER2- and HER+ tumours were relatively more frequent among women under age 45 years (HR-/HER2-: 23.6%, HER2+: 20.5%) compared to those within the screening age range (HR-/HER2-: 13.4%, HER2+: 13.9%) and the older age group (HR-/HER2-: 10.4%, HER2+: 11.5%).
Conclusions: The findings of our study shed light on potential areas for the improvement of BC screening programs (e.g., extending screening age group, adjusting screening frequency based on molecular subtype risk status) in Hungary and internationally, as well.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: